Our Life Sciences group is a multi-disciplinary team of more than 90 lawyers drawn from across our global network.
We have a reputation for far-sighted advice to some of the world’s leading life science companies and are described as "an efficient and client-oriented team" in Chambers Global 2010 Life Sciences edition.
Our support for pharmaceuticals, biotech, medical devices, nursing homes and other healthcare-related companies, as well as financial institutions operating in the sector, covers the spectrum: mergers and acquisitions (M&A), commercial transactions, including licensing and collaborations, intellectual property (IP) protection and patent disputes, capital markets and finance, regulatory and private equity.
Our international network enables us to deploy the skills of market-leading experts in a number of jurisdictions and we are well placed to advise on cross-border work, both contentious and non-contentious.
News & insights
Publications: 30 MARCH 2020
While the novel Covid-19 coronavirus is at the top of the agenda for businesses around the world, and for good reason, it is creating challenges for medical and healthcare systems and signalling fundamental change across the life sciences industry.Read more
Publications: 16 MARCH 2020
In order to contain the Coronavirus the German federal states as well as the German government have put strict measures into place. Schools and kindergartens have been closed as well as borders to most neighbouring states for private travel. In order to mitigate the economic consequences, the German government announced a comprehensive package of measures.Read more
Publications: 19 FEBRUARY 2020
On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement).Read more